Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247–50.
Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021;596:576–82.
Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors. Cell. 2020;183:860–74.
Park SY, Nam JS. The force awakens: metastatic dormant cancer cells. Exp Mol Med. 2020;52:569–81.
Dhanyamraju PK, Schell TD, Amin S, Robertson GP. Drug-tolerant persister cells in cancer therapy resistance. Cancer Res. 2022;82:2503–14.
Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of cancer resistance to immunotherapy. Front Oncol. 2020;10:1290.
O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2018;16:151–67.
Sehgal K, Portell A, Ivanova EV, Lizotte PH, Mahadevan NR, Greene JR, et al. Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2021;131. Available from: https://pubmed.ncbi.nlm.nih.gov/33151910/.
Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun. 2022;13:1606.
Catalán E, Jaime-Sánchez P, Aguilo N, Simon MM, Froelich CJ, Pardo J. Mouse cytotoxic T cell-derived granzyme B activates the mitochondrial cell death pathway in a Bim-dependent fashion. J Biol Chem. 2015;290:6868–77.
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299–309.
Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S, et al. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022;42:BSR20211812.
Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845–53. https://doi.org/10.1182/blood.V89.6.1845.
Pourzia AL, Olson ML, Bailey SR, Boroughs AC, Aryal A, Ryan J, et al. Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. Cell Death Dis. 2023;14. Available from: https://pubmed.ncbi.nlm.nih.gov/37055388/
Potter DS, Du R, Bhola P, Bueno R, Letai A. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. Cell Death Dis. 2021;12. Available from: https://pubmed.ncbi.nlm.nih.gov/34315868/
Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761.
Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020;38:872–890.e6.
Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020;13. Available from: https://pubmed.ncbi.nlm.nih.gov/32546544/
Pan R, Ryan J, Pan D, Wucherpfennig KW, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185:1521–1538.e18.
Song EZ, Wang X, Philipson BI, Zhang Q, Thokala R, Zhang L, et al. The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Mol Ther Oncolytics. 2022;27:288–304.
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015;7:275ra22.
Jiao Y, Cao F, Liu H. Radiation-induced cell death and its mechanisms. Health Phys. 2022;123:376.
Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 2004;53:153–9.
Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep Med. 2024;5:101471.
Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer. 2024;24:694–717.
Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol. 2023;20:799–813.
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69–80.
Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thoracic Oncol. 2021;16:1798–809.
Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intratumoral effector t cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11:68–79.
Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 2019;46. Available from: https://pubmed.ncbi.nlm.nih.gov/31585396/
Mesner PW, Budihardjo II, Kaufmann SH. Chemotherapy-induced apoptosis. Adv Pharmacol. 1997;41:461–99.
Waterhouse NJ, Sedelies KA, Browne KA, Wowk ME, Newbold A, Sutton VR, et al. A central role for Bid in granzyme B-induced apoptosis. J Biol Chem. 2005;280:4476–82.
Goping IS, Barry M, Liston P, Sawchuk T, Constantinescu G, Michalak KM, et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity. 2003;18:355–65.
Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14–8.
Chun N, Ang RL, Chan M, Fairchild RL, Baldwin WM, Horwitz JK, et al. T cell–derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death. JCI Insight. 2021;6:e148643.
Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev. 2014;25:453–72.
Chonghaile TN, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VDG, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129.
Potter DS, Du R, Bohl SR, Chow KH, Ligon KL, Bueno R, et al. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nat Commun. 2023;14. Available from: https://pubmed.ncbi.nlm.nih.gov/37210412/
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30.
Kalbasi A, Ribas A. Antigen presentation keeps trending in immunotherapy resistance. Clin Cancer Res. 2018;24:3239–41.
Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30:507–19.
Zhang W, Yuan S, Zhang Z, Fu S, Liu S, Liu J, et al. Regulating tumor cells to awaken T cell antitumor function and enhance melanoma immunotherapy. Biomaterials. 2025;316:123034.
Charles A, Janeway J, Travers P, Walport M, Shlomchik MJ. T cell-mediated cytotoxicity. 2001. https://www.ncbi.nlm.nih.gov/books/NBK27101/.
Halle S, Halle O, Förster R. Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo. Trends Immunol. 2017;38:432–43.
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309–37.
Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411–24.
Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006;580:2903–9.
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24:837–52.
Atilla PA, Atilla E. Resistance against anti-CD19 and anti-BCMA CAR T cells: recent advances and coping strategies. Transl Oncol. 2022;22:101459.
Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149:8131.
Davern M, Donlon NE, Sheppard A, Connell FO, Hayes C, Bhardwaj A, et al. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells. Transl Oncol. 2021;14:101062.
Lacour M, Hiltbrunner S, Lee SY, Soltermann A, Rushing EJ, Soldini D, et al. Adjuvant chemotherapy increases programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer recurrence. Clin Lung Cancer. 2019;20:391–6.
Cui JW, Li Y, Yang Y, Yang HK, Dong JM, Xiao ZH, et al. Tumor immunotherapy resistance: revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape. Biomed Pharmacotherapy. 2024;171:116203.
Stutvoet TS, Kol A, de Vries EGE, de Bruyn M, Fehrmann RSN, Terwisscha van Scheltinga AGT, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J Pathol. 2019;249:52–64.
Shen X, Jin X, Fang S, Chen J. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells. Cell Mol Biol Lett. 2023;28:53.
Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8. https://pubmed.ncbi.nlm.nih.gov/29170499/
Dadsena S, Jenner A, García-Sáez AJ. Mitochondrial outer membrane permeabilization at the single molecule level. Cell Mol Life Sci. 2021;78:3777.
Kalkavan H, Chen MJ, Crawford JC, Quarato G, Fitzgerald P, Tait SWG, et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell. 2022;185:3356–74.e22.
Vringer E, Heilig R, Riley JS, Black A, Cloix C, Skalka G, et al. Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. EMBO J. 2024;43:904–30.
Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9:1–37.
Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2:823.
Li F, Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta Rev Cancer. 2010;1805:167–80.
Perez R, Crombet T, de Leon J, Moreno E. A view on EGFR-targeted therapies from the oncogene-addiction perspective. Front Pharmacol. 2013;4:53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3636470/